Mayo Graduate school(USA) 藥理學博士 1986.6~1991.2
高雄醫學院醫學系 醫學士 1977.9~1984.6

財團法人醫藥品查驗中心 臨床組組長 1998.10~2002.6
Methodist Primary Care Association in USA, Senior health center Physician 1996.3~1998.9

中華民國內科醫學會會員

期刊論文（Journal Articles）
• Mau BL, Powis G.
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds.
Biochem Pharmacol (England). 1992; 43:1613–1620.
• Mau BL, Powis G.
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin: Relationship to inhibition of cell proliferation and decreased ribonucleotide reductase activity.
Biochem Pharmacol (England). 1992; 43:1621–1627.
• Lin YL, Mau BL, Chern HD, Chu ML.
What type of pivotal study design is appropriate for an investigational drug to manage chronic angle closure glaucoma?
Drug Info J. 2002; 36:499–500.
• Lin YL, Huang CH, Lin CL, Mau BL.
Compliance of clinical trial consent forms with international guidelines: Analysis of deficiencies.
Drug Info J. 2002; 36:17–19.
• Tzen CY, Mau BL.
Analysis of CD117-negative gastrointestinal stromal tumors.
World J Gastroenterol. 2005; 11:1052–1055.
• Mau BL, Lee HM, Tzen CY.
Identification of human-specific adaptation sites of ATP6.
Ann NY Acad Sci. 2005; 1042:142–147.
• Tzen CY, Mau BL, et al.
Is extramedullary plasmacytoma an oligoclonal tumor with clonal selection during tumor progression?
Histopathology. 2006; 48:463–477.
• Tzen CY, Wang MN, Mau BL.
Spectrum and prognostication of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
Eur J Surg Oncol. 2008; 34:563–568.
• Lai YL, Mau BL, et al.
PIK3CA Exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Ann Surg Oncol. 2008; 15:1064–1069.
• Mau BL, Huang YW, Wu CY, Tzen CY.
Diffuse large B cell lymphomas in the intestine and lung: Two lymphomas or lymphoma spread?
Clin Mol Med. 2008; 1:30–32.
• Tzen CY, Mau BL, Hsu HJ.
Analysis of disease-associated ND4 mutations: How do we know which mutation is pathogenic?
Mitochondrion. 2007; 7:151–156.
• Tzen CY, Mau BL, Wu TY.
ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis?
Mitochondrion. 2007; 7:273–278.
生物醫學雜誌（Biomedical Journal Articles）
• 褚乃銘、毛蓓領。
專家對談—侵襲性乳癌之標靶治療。
生物醫學。2008; 1:153–157.
• 毛蓓領。
乳癌療法的回顧與分子指標。
生物醫學。2009; 2:162–172.
• 毛蓓領。
專家評論—糖尿病的藥物治療。
生物醫學。2010; 3:369–373.
• 毛蓓領。
氣喘的臨床回顧。
生物醫學。2012; 5:147–153.
• 毛蓓領。
黑色素瘤之KIT突變檢驗。
生物醫學。2013; 6:144–146.
• 毛蓓領。
抗體藥品複合物。
生物醫學。2014; 7:33–36.
• 毛蓓領。
黑色素瘤治療新進展。
生物醫學。2014; 7:121–124.
• 毛蓓領。
慢性B型肝炎的干擾素療法。
生物醫學。2015; 8:43–46.
• 毛蓓領。
輔酶Q10是藥品嗎？
生物醫學。2015; 8:172–176.
• 毛蓓領, 曾嶔元。
遺傳性癌症之基因檢測。
生物醫學。2016; 9:24–29.
• 毛蓓領。
嗜鉻細胞瘤之臨床回顧。
生物醫學。2016; 9:156–165.
• 毛蓓領。
胃腸胰神經內分泌瘤的症狀與治療。
生物醫學。2016; 9:168–182.
• 毛蓓領, 曾嶔元。
精準醫學之生物標記。
生物醫學。2018; 11(4):251–253.
會議論文 / 摘要（Conference Abstracts）
• Mau BL, Lee HM, Tzen CY.
Identification of human-specific adaptation sites of ATP6.
The 2nd ASMRM, Taipei, April 1–2, 2004.
• Tzen CY, Wang MN, Mau BL.
Spectrum and Prognostication of KIT and PDGFRA Mutation in Gastrointestinal Stromal Tumors.
13th ESSO Congress, Venice, Nov 30–Dec 2, 2006.
• Wu TY, Mau BL, Tzen CY.
Prognostication and Mechanism of ND4 Mutations in Transitional Cell Carcinoma.
The 4th ASMRM, Seoul, Feb 2–3, 2007.
• Hsu HJ, Cheng WH, Wang MN, Mau BL, et al.
PIK3CA Mutations in Nasopharyngeal Carcinoma.
The SKCC 2007 Conference, San Diego, Mar 5–7, 2007.
• Liu WY, Hsu HJ, Mau BL, Tzen CY.
Mutations and Polymorphisms of ATP6 Gene in Type 2 Diabetes Mellitus.
The 4th ASMRM, Seoul, Feb 2–3, 2007.
• Mau BL, Tzen CY.
Prediction of KIT mutation in gastrointestinal stromal tumors by immunoprofile of the tumor cells.
AACR-NCI-EORTC Conference, San Francisco, Oct 22–26, 2007.